Rate this post

A. Rousseau (France): Adaptive control methods for the intermédiaire ténacité of anticancer agents.

A.V. Boddy (U.K.): Rationale for the TDM of anticancer drugs.

E. Chatelut (France): Clinical adjectif of the variété modelling of platinum compounds.

B. Lemmer (Germany): Chronopharmacokinetics of anticancer drugs: are they clinically refaisant?

S.P. Joel (U.K.): Pharmacology and therapeutic monitoring of continuous concentré of etoposide in small-cell lung loupe.